Elkhart Clinic

The trials here

What the 24 trials at this site are about, from their registry records.

Conditions

• Ovarian cancer4 trials
• Colorectal cancer3 trials
• Lung cancer3 trials
• Childhood cancers2 trials
• Metastatic breast cancer2 trials
• Neuroendocrine tumours2 trials
• Triple-negative breast cancer2 trials
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• and 5 more

Phase

• Phase 318 trials
• Phase 25 trials
• Phase 2/31 trial

Status

• Active, not recruiting13 trials
• Completed11 trials

Lead sponsor

• National Cancer Institute (NCI)20 trials
• Alliance for Clinical Trials in Oncology2 trials
• SWOG Cancer Research Network2 trials

Running trials

• Active, not recruiting

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

  NCT01841736· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

  NCT01856192· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT01708954· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

  NCT01081262· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

  NCT00977574· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

  NCT00843882· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

  NCT00565851· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

  NCT00569127· Phase 3· National Cancer Institute (NCI)· Source

Closed trials

• Completed

  MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

  NCT01805076· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source